Apixaban Formulations
Patent No. EP3017811 (titled "Apixaban Formulations") was filed by Bristol Myers Squibb on Feb 24, 2011. The application was issued on Dec 5, 2018.
Patent Summary
Tablets containing apixaban for treating thromboembolic disorders with improved bioavailability by using apixaban particles with a maximum size cutoff of less than 89 microns. The tablets are made by a dry granulation process that produces apixaban particles with a d90 size below 89 microns. This allows consistent in vivo dissolution and exposure compared to larger particles. The smaller particle size improves absorption and therapeutic efficacy compared to tablets with larger particles made by wet granulation or using large apixaban particles.
Patent Family
Patent Oppositions (10)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents
EP3017811
- Application Number
- EP15190823A
- Filing Date
- Feb 24, 2011
- Status
- Revoked
- Mar 22, 2024
- Publication Date
- Dec 5, 2018
- External Links
- Slate, Register , Google Patents